Posted by Michael Wonder on 15 Dec 2022
Cabozantinib maleate for patients with previously treated advanced hepatocellular carcinoma
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of cabozantinib maleate in the NHS in England.
Cabozantinib maleate is recommended as an option for the treatment of adults with advanced hepatocellular carcinoma who have been treated with sorafenib tosylate only if:
- They have Child–Pugh grade A liver impairment and an Eastern Cooperative Oncology Group performance status of 0 or 1
- Ipsen provides cabozantinib maleate according to the commercial arrangement
